Ibrance (palbociclib) vs Enhertu (fam-trastuzumab deruxtecan-nxki)
Ibrance (palbociclib) vs Enhertu (fam-trastuzumab deruxtecan-nxki)
Ibrance (palbociclib) is a CDK4/6 inhibitor used in combination with certain hormonal therapies to treat HR-positive, HER2-negative advanced or metastatic breast cancer. Enhertu (fam-trastuzumab deruxtecan-nxki) is an antibody-drug conjugate specifically designed for the treatment of patients with HER2-positive breast cancer, and it has also shown efficacy in HER2-low expressing breast cancer. The choice between Ibrance and Enhertu would largely depend on the patient's specific breast cancer biomarkers (HR-positive/HER2-negative for Ibrance and HER2-positive or HER2-low for Enhertu), as well as the overall treatment plan determined by the healthcare provider.
Difference between Ibrance and Enhertu
| Metric | Ibrance (palbociclib) | Enhertu (fam-trastuzumab deruxtecan-nxki) |
|---|---|---|
| Generic name | Palbociclib | Fam-trastuzumab deruxtecan-nxki |
| Indications | HR-positive, HER2-negative breast cancer | HER2-positive breast cancer, HER2-positive gastric cancer |
| Mechanism of action | CDK4/6 inhibitor | HER2-directed antibody and topoisomerase inhibitor conjugate |
| Brand names | Ibrance | Enhertu |
| Administrative route | Oral | Intravenous |
| Side effects | Neutropenia, leukopenia, infections, fatigue | Nausea, fatigue, vomiting, alopecia, constipation |
| Contraindications | Hepatic impairment, existing neutropenia | Interstitial lung disease, pneumonitis, previous severe hypersensitivity reactions |
| Drug class | Antineoplastic agent, kinase inhibitor | Antineoplastic agent, antibody-drug conjugate |
| Manufacturer | Pfizer | Daiichi Sankyo and AstraZeneca |
Efficacy
Efficacy of Ibrance (Palbociclib) in Breast Cancer
Ibrance (palbociclib) is a targeted therapy that has shown efficacy in the treatment of certain types of breast cancer. Specifically, it is used for hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic breast cancer. Palbociclib works by inhibiting cyclin-dependent kinases (CDK) 4 and 6, which are proteins that regulate cell division. By blocking these proteins, Ibrance can help to stop cancer cells from growing and dividing.
Clinical trials have demonstrated that when used in combination with hormone therapy, such as an aromatase inhibitor or fulvestrant, Ibrance can significantly improve progression-free survival compared to hormone therapy alone. This has been observed in both first-line and subsequent treatment settings. However, while Ibrance has been associated with delaying disease progression, an improvement in overall survival has not been consistently demonstrated across all studies.
Efficacy of Enhertu (Fam-Trastuzumab Deruxtecan-nxki) in Breast Cancer
Enhertu (fam-trastuzumab deruxtecan-nxki) is an antibody-drug conjugate that has shown efficacy in the treatment of HER2-positive breast cancer. This medication is designed to deliver chemotherapy directly to cancer cells by targeting the HER2 protein, which is overexpressed in some breast cancer cells. Enhertu binds to HER2 on the surface of cancer cells, allowing the attached chemotherapy to enter the cells and cause cell death.
Clinical studies have indicated that Enhertu can lead to significant responses in patients with HER2-positive metastatic breast cancer who have previously received two or more anti-HER2 therapies. The treatment has been associated with high rates of objective response and has been shown to improve progression-free survival. Furthermore, Enhertu has also demonstrated a notable improvement in overall survival for patients with advanced HER2-positive breast cancer, marking a significant advancement in the treatment of this aggressive form of the disease.
Regulatory Agency Approvals
Ibrance
-
European Medical Agency (EMA), European Union
-
Food and Drug Administration (FDA), USA
-
Health Canada
-
Therapeutic Goods Administration (TGA), Australia
-
Medsafe (NZ)
Enhertu
-
European Medical Agency (EMA), European Union
-
Food and Drug Administration (FDA), USA
-
Pharmaceuticals and Medical Devices Agency (PMDA), Japan
Access Ibrance or Enhertu today
If Ibrance or Enhertu are not approved or available in your country (e.g. due to supply issues), you can access them via Everyone.org.
How it works
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Breeze through the paperwork
We'll guide you through the required documents for importing unapproved medicine, ensuring you have all the necessary information.
Get a personalized quote
We’ll prepare a quote for you, including medicine costs and any shipping, administrative, or import fees that may apply.
Receive your medicine
Accept the quote and we’ll handle the rest - sourcing and safely delivering your medicine.
Some text on this page has been automatically generated. Speak to your physician before you start a new treatment or medication.
Let's talk
If you have any questions, call us or send us a message through WhatsApp or email:
Contact us